MiR-520h is crucial for DAPK2 regulation and breast cancer progression

Chih-Ming Su, M. Y. Wang, Charlie Hong, Hsin-An Chen, Y. H. Su, Chih-Hsiung Wu, Ming-Te Huang, Yi Wen Chang, Shih Sheng Jiang, Shian-Ying Sung, Jang Yang Chang, Li Tzong Chen, Pai Sheng Chen, Jen Liang Su

研究成果: 雜誌貢獻文章

17 引文 (Scopus)

摘要

MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.
原文英語
頁(從 - 到)1134-1142
頁數9
期刊Oncogene
35
發行號9
DOIs
出版狀態已發佈 - 三月 3 2016

指紋

Death-Associated Protein Kinases
MicroRNAs
Breast Neoplasms
Drug Resistance
3' Untranslated Regions
Paclitaxel
Computational Biology

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

引用此文

Su, C-M., Wang, M. Y., Hong, C., Chen, H-A., Su, Y. H., Wu, C-H., ... Su, J. L. (2016). MiR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene, 35(9), 1134-1142. https://doi.org/10.1038/onc.2015.168

MiR-520h is crucial for DAPK2 regulation and breast cancer progression. / Su, Chih-Ming; Wang, M. Y.; Hong, Charlie; Chen, Hsin-An; Su, Y. H.; Wu, Chih-Hsiung; Huang, Ming-Te; Chang, Yi Wen; Jiang, Shih Sheng; Sung, Shian-Ying; Chang, Jang Yang; Chen, Li Tzong; Chen, Pai Sheng; Su, Jen Liang.

於: Oncogene, 卷 35, 編號 9, 03.03.2016, p. 1134-1142.

研究成果: 雜誌貢獻文章

Su, C-M, Wang, MY, Hong, C, Chen, H-A, Su, YH, Wu, C-H, Huang, M-T, Chang, YW, Jiang, SS, Sung, S-Y, Chang, JY, Chen, LT, Chen, PS & Su, JL 2016, 'MiR-520h is crucial for DAPK2 regulation and breast cancer progression', Oncogene, 卷 35, 編號 9, 頁 1134-1142. https://doi.org/10.1038/onc.2015.168
Su, Chih-Ming ; Wang, M. Y. ; Hong, Charlie ; Chen, Hsin-An ; Su, Y. H. ; Wu, Chih-Hsiung ; Huang, Ming-Te ; Chang, Yi Wen ; Jiang, Shih Sheng ; Sung, Shian-Ying ; Chang, Jang Yang ; Chen, Li Tzong ; Chen, Pai Sheng ; Su, Jen Liang. / MiR-520h is crucial for DAPK2 regulation and breast cancer progression. 於: Oncogene. 2016 ; 卷 35, 編號 9. 頁 1134-1142.
@article{5f0812960ba04f8099ffe13e10a1ef31,
title = "MiR-520h is crucial for DAPK2 regulation and breast cancer progression",
abstract = "MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.",
author = "Chih-Ming Su and Wang, {M. Y.} and Charlie Hong and Hsin-An Chen and Su, {Y. H.} and Chih-Hsiung Wu and Ming-Te Huang and Chang, {Yi Wen} and Jiang, {Shih Sheng} and Shian-Ying Sung and Chang, {Jang Yang} and Chen, {Li Tzong} and Chen, {Pai Sheng} and Su, {Jen Liang}",
year = "2016",
month = "3",
day = "3",
doi = "10.1038/onc.2015.168",
language = "English",
volume = "35",
pages = "1134--1142",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - MiR-520h is crucial for DAPK2 regulation and breast cancer progression

AU - Su, Chih-Ming

AU - Wang, M. Y.

AU - Hong, Charlie

AU - Chen, Hsin-An

AU - Su, Y. H.

AU - Wu, Chih-Hsiung

AU - Huang, Ming-Te

AU - Chang, Yi Wen

AU - Jiang, Shih Sheng

AU - Sung, Shian-Ying

AU - Chang, Jang Yang

AU - Chen, Li Tzong

AU - Chen, Pai Sheng

AU - Su, Jen Liang

PY - 2016/3/3

Y1 - 2016/3/3

N2 - MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.

AB - MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84959485225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959485225&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.168

DO - 10.1038/onc.2015.168

M3 - Article

C2 - 25982274

AN - SCOPUS:84959485225

VL - 35

SP - 1134

EP - 1142

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 9

ER -